Shares of Wockhardt, a pharmaceutical company based in India, rose by 8.57% to ₹1,550 on Tuesday following a robust performance in the March quarter and strong full-year earnings. The company reported a net profit of ₹164 crore for Q4FY26, a turnaround from a loss of ₹45 crore in the same quarter the previous year. Revenue surged 30% year-on-year to ₹965 crore, up from ₹743 crore in Q4FY25, while EBITDA saw an impressive growth of 147%, reaching ₹196 crore compared to ₹79 crore a year earlier.

For the full fiscal year 2026, Wockhardt's revenue totaled ₹3,373 crore, reflecting an 11% increase from ₹3,033 crore in FY25. The EBITDA for the full year rose by 51% to ₹630 crore, indicating improved operational performance across various segments. A significant contributor to this growth was the company's biotech operations, which generated ₹252 crore in Q4FY26, marking a 126% increase year-on-year. The biotech segment's full-year revenue also rose by 27%, driven by strong growth in emerging markets, surpassing 34% growth.

Wockhardt's market capitalization currently stands at ₹23,155 crore, and its stock has experienced a 13% increase over the past month. The shares are trading between a 52-week high of ₹1,868.80 and a low of ₹1,086.70. The company has made significant strides in its product pipeline, with numerous filings and approvals in both biosimilars and new chemical entities (NCEs).